TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases.

Journal Article (Journal Article;Review)

Aberrant tumour necrosis factor (TNF) signalling is a hallmark of many inflammatory diseases including rheumatoid arthritis (RA), irritable bowel disease and lupus. Maladaptive TNF signalling can lead to hyper active downstream nuclear factor (NF)-κβ signalling in turn amplifying a cell's inflammatory response and exacerbating disease. Within the TNF intracellular inflammatory signalling cascade, transforming growth factor-β-activated kinase 1 (TAK1) has been shown to play a critical role in mediating signal transduction and downstream NF-κβ activation. Owing to its role in TNF inflammatory signalling, TAK1 has become a potential therapeutic target for the treatment of inflammatory diseases such as RA. This review highlights the current development of targeting the TNF-TAK1 signalling axis as a novel therapeutic strategy for the treatment of inflammatory diseases.

Full Text

Duke Authors

Cited Authors

  • Totzke, J; Scarneo, SA; Yang, KW; Haystead, TAJ

Published Date

  • September 2020

Published In

Volume / Issue

  • 10 / 9

Start / End Page

  • 200099 -

PubMed ID

  • 32873150

Pubmed Central ID

  • PMC7536066

Electronic International Standard Serial Number (EISSN)

  • 2046-2441

Digital Object Identifier (DOI)

  • 10.1098/rsob.200099

Language

  • eng

Conference Location

  • England